** Kura Oncology KURA.O shares jump 14% to $6.49 in pre-market trading
** KURA and Japan-based Kyowa Kirin 4151.T say the US FDA accepted marketing application for ziftomenib
** The drug, if approved, could be used to treat patients with acute myeloid leukemia, a type of blood cancer
** The disease affects about 22,000 people in the US every year, according to American Cancer Society
** Ziftomenib is a potential first-of-its-kind treatment for this aggressive form of leukemia, the cos say
** The FDA has granted priority review and is likely to decide by November 30 this year, they added
** YTD, stock down 34.7%, as of last close
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。